TITLE

Reclast

PUB. DATE
July 2009
SOURCE
Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Reclast (zoledronic acid) Injection from Novartis Pharmaceuticals Corp. as a therapy postmenopausal osteoporosis prevention. It notes that the drug is already approved as a once-yearly infusion to treat the disease and Paget's disease of the bone.
ACCESSION #
42732611

 

Related Articles

  • Afinitor Targets a Form Of Pancreatic Cancer.  // Chain Drug Review;6/6/2011, Vol. 33 Issue 10, p42 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to Novartis Pharmaceuticals Corp.'s Afinitor drugs which can used for the treatment of progressive neuroendocrine tumors (NET) in East Hanover, New Jersey.

  • FDA Approves Amgen's Prolia for Treatment of Postmenopausal Women with Osteoporosis.  // BioPharm International;Jul2010, Vol. 23 Issue 7, p14 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Prolia, a postmenopausal treatment for women with osteoporosis at high risk for fracture, manufactured by Thousand Oaks, California-based Amgen Inc.

  • New therapy for Paget's disease.  // Drug Topics;5/7/2007, Vol. 151 Issue 9, p8 

    The article reports that the U.S. Food and Drug Administration has approved zoledronic acid (Reclast) from Novartis AG for the treatment of Paget's disease in both men and women. The drug is indicated for patients with elevations in serum alkaline phosphatase of two or more time the upper limit...

  • Recently Approved.  // Pharmaceutical Representative;Oct2007, Vol. 37 Issue 10, p14 

    The article offers news briefs related to drug approval by the U.S. Food and Drug Administration (FDA). Novartis Pharmaceuticals Corp.'s Reclast injection has been approved to treat postmenopausal osteoporosis. Janssen LP's Risperdal drug for treating schizophrenia in adolescents has been...

  • Oral Drug for Iron Overload.  // FDA Consumer;Jan/Feb2006, Vol. 40 Issue 1, p5 

    The article reports that the U.S. Food and Drug Administration approved a new drug for treating chronic iron overload called Exjade, which is manufactured by Novartis Pharmaceutical Corp., on November 2005. It describes previous treatment for iron overload and discusses the outcome of clinical...

  • Pipeline.  // Medical Marketing & Media;Mar2008, Vol. 43 Issue 3, p12 

    The article offers information on several drugs approved by the U.S. Food and Drug Administration. These include Tekturna HCT from Novartis Pharmaceuticals Corp. as a single tablet combination of two high blood pressure medicines designed to work together to lower blood pressure. Also include is...

  • PHARMACY CORNER.  // Oncology Nursing Forum;May2007, Vol. 34 Issue 3, p737 

    The article offers news briefs on issues related to pharmaceuticals in the U.S. A Cancer and Leukemia Group B phase III clinical trial has found that arsenic trioxide may improve the condition of patients with acute promyelocytic leukemia (APL). Novartis Pharmaceuticals has unveiled the drug...

  • NEW FORMULATIONS.  // Drug Topics;6/5/2006, Vol. 150 Issue 11, p45 

    The article reports on the new higher-dose formulations approval of high blood pressure treatment drug, Diovan HCT from Novartis Pharmaceuticals Inc. by the U.S. Food and Drug Administration in 2006. The two new formulations for blood pressure medication are 320 over 12.5 milligram and 320 over...

  • Paget's disease.  // Geriatrics;Jun98, Vol. 53 Issue 6, p27 

    Reports that the United States Food and Drug Association approved risedronate sodium for the treatment of Paget's disease. Details on a study carried out on patients treated with risedronate; Recommended daily dose; Types of patients who should not use the drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics